As we are all too aware, Australia scores poorly on the translation of its research discoveries into new products and services. We need to improve the extent to which Australia’s research effort is directed to the questions and problems of greatest importance and how effectively our research is applied to provide solutions.
Bringing research and innovation together in the one Strategic Plan provides an opportunity to drive these improvements and to overcome some of the historic divides between programs to invest smartly in research and in programs to support and drive innovation. In addition to the research, innovation and investment communities, active engagement with the state and territory governments will be vital; it needs to be a ‘whole of governments’ strategy.
Just as importantly, the 2030 Strategic Plan needs a whole of community communication strategy to ensure all levels of society understand the imperative for a greater and more strategic investment in research, technology and innovation, and the benefits this can bring as we plan for the Australia we want in 2030.
Download Research Australia’s submission here.
Research Australia has made a submission to the Senate Select Committee Inquiry into Funding for Research into Cancers with Low Survival Rates. Many of the Terms of Reference have relevance beyond brain cancers, cancers with low survival rates and low incidence cancers; our submission approaches the Inquiry from this broader perspective.
Government funding available for health and medical research is finite. While cancers with low survival rates are undoubtedly worthy of more funding, any increase in funding for one area has implications for the funding available to other disease areas. Improvements in survival are related to global research rather than specifically to the volume or subject of Australian research, and it is important that Australian researchers and patients have access to, and contribute to this global effort. This is particularly relevant for low incidence cancers and other rare diseases, because the number of patients in Australia is likely to be low and appropriate research collaborators are in many cases likely to be based overseas. Thus, when allocating funding we also need to consider the level of funding available and the research activity undertaken globally.
Research Australia also suggests there is merit in looking at approaches taken by other countries. This includes strategies such as rare disease policies that have been established in more than 20 countries as a means of providing a policy framework for a considered and comprehensive approach to the provision of research, diagnosis and access to treatment for rare diseases. In an area where the only available therapies are often experimental, a single policy that brings research, diagnosis and treatment together is valuable.
Read the full Research Australia submission today.
The Therapeutic Goods Amendment (2016 Measures No. 1) Bill 2016 (the Bill) is part of the Government’s response to the recommendations of the review of Medicines and Medical Devices Regulation (MMDR), and the legislation is supported by Research Australia’s submission to the inquiry by the Senate Standing Committees on Community Affairs.
The aim of the Review’s recommendations is to improve the processes for the approval of medicines and medical devices by the Therapeutic Goods Administration. Together the regulatory reforms are expected to reduce the administrative burden on applicants and make the approval process faster without jeopardising the safety of consumers.
Achieving this aim will provide consumers with earlier access to potentially lifesaving new medicines and devices. It is also an effective means of supporting Australia’s medical device and medicines industries; by accelerating their pathway to market it will enable them to become profitable more quickly, providing them with more resources to pursue the international markets needed to be truly successful and profitable.
Research Australia submission TGA Bill
Research Australia’s submission to Treasury in response to the discussion paper on Social Impact Investing has advocated that interventions designed to improve health outcomes be explicitly acknowledged as within the scope of the proposed social investing framework.
Research Australia believes that Social Impact Investing could be an effective mechanism for funding and evaluating some pilot projects and clinical trials designed to implement and evaluate new evidence based practices and interventions. The benefits of implementing successful new interventions include better population health, improved patient care, and efficiency gains in the Australian healthcare system. These provide quantifiable social and financial gains that make the funding of these measures amenable to Social Impact Investing.
Research Australia Submission Social Impact Investing
CRCs have played a key role in the translation of Australian health and medical research. Research Australia’s response to the Government’s consultation on Themes and Priorities for the CRC Programme took the opportunity to advocate for the reinstatement of Public Good CRCs, which are specifically excluded by the most recent Guidelines for the CRC Programme.
Research Australia’s Submission – CRC Themes Consultation
Research Australia has provided a response to the Chief Scientist’s Research Infrastructure Draft Roadmap, released in late 2016. Research Australia’s submission has addressed the proposal for a new national advisory group, suggesting the functions of this group could be preformed by existing bodies. It has also emphasised the importance of engagement with state and territory governments in relation to investment and reiterated the importance of workforce planning for a skilled workforce to build, maintain and use research infrastructure. Research Australia has called for greater transparency in the funding of major research infrastructure and suggested some further clarity about the circumstances in which the national interest can be invoked to justify new infrastructure spending.
Research Infrastructure Roadmap Submission
In its pre-Budget submission to the Treasurer, Research Australia has urged the Government to remain committed to the full implementation of the National Innovation and Science Agenda, continue funding of the MRFF’s capital in accordance with the existing timetable, and emphasised the need to at least maintain real levels of funding for the NHMRC and ARC grant programs.
The submission also raises the looming issue of the funding of indirect research costs associated with MRFF grants. Research Australia has called for MRFF grants to be included as Category 1 income for universities’ Research Block Grants and for their inclusion in the IRIISS scheme for MRIs in the short term, and echoes the MRFF Advisory Board’s call for a whole of government approach to this issue in the longer term.
Pre Budget Submission
The Productivity Commission’s Draft Report on Public Sector Data Availability and Use, part of a 12 month Inquiry, has highlighted the public benefits of improving access to public data and has proposed significant reforms, including to improve access to data for researchers and to make researchers’ own data more accessible. While Research Australia is broadly supportive of the Commission’s draft recommendations, we have made substantive responses in relation to a number; particularly some that would affect the way research is conducted and funded.
As the quantities of data collected about all of us grows, so does our capacity to utilise this data for the benefit of all. As the Draft Report has identified, there is evidence that community attitudes to data and questions of privacy and security are changing, and legislation and government practices need to change to both reflect this change and enable us to harness this data as a valuable resource. Now is the time to act if we are to make the most of the opportunities public data provides to improve the delivery of government services and the health of our community, and to create the new economic opportunities and jobs of tomorrow. The Commission’s Draft Report is a very important step in what Research Australia acknowledges will be a long but fruitful journey in harnessing the transformative power of data in contemporary society.
Response to Productivity Commission Data Availability Draft Report December 2016
Research Australia’s submission in response the draft Fifth National Mental Health Plan has highlighted the Plan’s failure to include health and medical research.
Research Australia is concerned that the Fifth Plan is currently a missed opportunity to make better use of Australia’s significant capacity in health and medical research to help deliver the Plan’s vision of healthier Australians, faster and more complete recoveries from mental illness and more responsive and effective services.
The draft Fifth Plan calls for significant reform and innovation in the way we deliver mental health services in Australia, and the health and medical research sector is well placed to help inform, design, implement and evaluate these reforms. Research Australia believes the Fifth Plan provides an opportunity to improve the integration of the mental health system with the health and medical research sector, and to better utilise and direct research towards the Plan’s priorities. Our submission has highlighted some of the many ways in which health and medical research can contribute. Submission for 5th Mental Health Plan
Research Australia has made two submissions into the federal government’s R&D Tax Incentive review.
R&D Tax Incentive Submission 2016
R&D Tax Incentive Submission 2015
Research Australia supports the report’s recommendations to:
- maintain the current eligibility criteria
- introduce an incentive to encourage collaboration with publicly funded researchers
- to release more information about claimants.
Research Australia has opposed the application of a new $2 million cap to small caps that are seeking to commercialise HMR and proposed a modification to a recommendation that would limit the R&D Tax Incentive to more research intensive companies.
The Government will now consider the recommendations of the Review together with the responses from the public consultation and then formulate its response, which is expected to be subject to another round of consultation, probably early next year.